Glaxosmithkline Share News (GSK)

Skyepharma Confident In 2015 Outlook As Momentum Continues

Dividends Calendar - Week Ahead

Monday broker round-up

RBS: Credit Suisse reiterates underperform and 320p target. GlaxoSmithKline: Deutsche reiterates hold and lowers target to 1,540p from 1,600p. HSBC: Exane BNP reiterates underperform and 600p target. Lloyds: Credit Suisse reiterates neutral and 72p target. Sage Group: Goldman Sachs reiterates neu

Dividends Calendar - Week Ahead

Ex-divs to take 12.34 points off FTSE 100 on May 14

LONDON, May 11 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by market-mak

Dividends Calendar - Week Ahead

Hunt for AIDS cure accelerates as GSK and U.S. experts link up

* GSK commits $20 mln to new HIV Cure centre at Chapel Hill * Cure for AIDS on agenda following recent advances * Research will focus on approaches such as "shock and kill" By Ben Hirschler LONDON, May 11 (Reuters) - Britain's GlaxoSmithKline , which decided last week to r

Dividends Calendar - Week Ahead

Dividends Calendar - Week Ahead

UPDATE 2-New GSK chairman backs CEO Witty to stay at helm

(Adds comments on dividend, drug sector valuations) By Ben Hirschler LONDON, May 7 (Reuters) - GlaxoSmithKline's new chairman Philip Hampton has thrown his support behind the company's current structure and chief executive despite pressure from some shareholders for a change. In

Thursday tips round-up: GlaxoSmithKline, Sage

GlaxoSmithKline's decision not to proceed with the sale of part of its HIV unit, announced as part of its strategy update on 6 May, was the right one. It would pocket $10bn from such a sale but the unit is also the source of the quickest revenue growth at the company, with sales up 15% last year. Th

Thursday broker round-up

Morrison: Shore Capital reiterates buy. Direct Line Insurance Group: Canaccord Genuity reiterates buy and 350p target. BAE Systems: Charles Stanley reiterates accumulate. GlaxoSmithKline: UBS reiterates buy and 1,700p target. Aviva: Panmure Gordon reiterates buy and raises target to 660p from 600

New GSK chairman backs CEO Witty to stay at helm

LONDON, May 7 (Reuters) - GlaxoSmithKline's new chairman Philip Hampton expressed support for the company's current structure and its chief executive on Thursday while speaking to reporters after the drugmaker's annual meeting. Hampton said he hopes CEO Andrew Witty will continue to run GSK

Dividends Calendar - Week Ahead

BUZZ-GlaxoSmithKline: hit as 2015 gloom outweighs long-term hope

** GlaxoSmithKline second biggest FTSE 100 faller, down 3.4 pct, as analysts downgrade near-term estimates after drugmaker warns of "high teens" percentage fall in 2015 EPS ** Brokerages Bernstein and Bryan Garnier both cut price targets. Bernstein analyst Tim Anderson says 2015 guidance "